False-negative findings on mpMRI scans of men with clinically significant prostate cancer

Some people aren’t going to be happy about the following data, but they come from one of the most sophisticated prostate cancer imaging centers in the world … and they make it very clear indeed that multiparametric MRI scanning (mpMRI) is less than perfect in identification of risk for prostate cancer. … READ MORE …

How accurate is an initial, negative prostate biopsy at predicting risk for prostate cancer-specific mortality?

A new paper in this week’s issue of Lancet Oncology comes from analysis of data on the outcomes of > 60,000 men given a prostate biopsy for risk of prostate cancer in Denmark between 1995 and 2011 and followed for up to 20 years thereafter. … READ MORE ..

New consensus statement on monitoring for prostate cancer risk after a first, negative biopsy

There has been no really clear and formal guidance available on how to monitor patients for risk of prostate cancer after a first, negative, standard, 12-core, systematic biopsy. New guidance from the American Urological Association (AUA) and the Society of Abdominal Radiology (SAR) may be helpful in addressing this situation. … READ MORE …

“False positive” data from the European screening trial and other matters

The “game” of retrospectively analyzing every possible piece of data from the European Randomized Screening Study for Prostate Cancer (ERSPC) has been under way for a while now … and we can expect this game to produce lots and lots of controversial information and media coverage. But much of the data from these subset analyses will need to be treated with great caution. … READ MORE …